|
26 Jan 2023 |
Mersana Therapeutics Announces Initiation of Phase 1 Trial of XMT-2056 in HER2-Expressing Tumors
|
|
26 Jan 2023 |
Enhertu approved in the EU as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer
|
|
25 Jan 2023 |
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy in First-Line Advanced or Unresectable Biliary Tract Cancer in KEYNOTE-966 Trial
|
|
25 Jan 2023 |
Merck Announces KEYNOTE-991 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Enzalutamide and Androgen Deprivation Therapy in Patients With Metastatic Hormone-Sensitive Prostate Cancer to Stop for Futility
|
|
24 Jan 2023 |
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
|
|
24 Jan 2023 |
Amolyt Pharma Announces Research Agreement and Licensing Option with XOMA
|
|
24 Jan 2023 |
AltruBio Announces First Patient Dosed in Phase 1 Trial of Next-Generation Immune Checkpoint Enhancer ALTB-268 for the Treatment of Ulcerative Colitis
|
|
24 Jan 2023 |
Memo Therapeutics AG Announces Positive Phase I Data with AntiBKV for Treatment of BKV Infection in Renal Transplant Patients
|
|
23 Jan 2023 |
Disc Medicine Announces Exclusive Licensing Agreement with Mabwell Therapeutics for Novel Anti-TMPRSS6 Monoclonal Antibodies to Modulate Iron Homeostasis
|
|
20 Jan 2023 |
Summit Therapeutics Closes Deal with Akeso Inc. to In-License Breakthrough Innovative Bispecific Antibody
|
|
20 Jan 2023 |
Dr. Reddy’s successfully completes full set of clinical studies of its rituximab biosimilar for filing in the U.S., Europe
|
|
20 Jan 2023 |
Jazz Pharmaceuticals and Zymeworks Announce 84% Overall Survival at 18 Months from Phase 2 Trial Evaluating Zanidatamab in HER2-Expressing Metastatic Gastroesophageal Adenocarcinoma
|
|
20 Jan 2023 |
U.S. Food and Drug Administration Issues Complete Response Letter for Accelerated Approval of Donanemab
|
|
20 Jan 2023 |
SOTIO Doses First Patient in AURELIO-05 Phase 2 Trial of Nanrilkefusp Alfa in Combination with Cetuximab
|
|
19 Jan 2023 |
Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial
|
|
18 Jan 2023 |
Keymed Biosciences | The Latest Results from the Phase Ia Clinical Study of CMG901 was presented at the 2023 ASCO GI CANCERS SYMPOSIUM
|
|
17 Jan 2023 |
IGM Biosciences Initiates First-in-Human Clinical Trial of IGM-7354 in Solid Tumors
|
|
17 Jan 2023 |
Henlius' Novel Anti-PD-1 mAb HANSIZHUANG (Serplulimab) Approved for the Treatment of ES-SCLC
|
|
17 Jan 2023 |
Leap Therapeutics Acquires Flame Biosciences
|
|
17 Jan 2023 |
Asher Bio Announces Dosing of First Patient in Phase 1a/1b Clinical Trial of AB248, a Cis-targeted IL-2 Immunotherapy Product Candidate, for the Treatment of Locally Advanced or Metastatic Solid Tumors
|
|
17 Jan 2023 |
Dong-A ST Demonstrates Therapeutic Equivalence Between DMB-3115 and Stelara in Global Phase III
|
|
16 Jan 2023 |
China NMPA Approves Bio-Thera Solutions’ BAT1806, A Biosimilar to Actemra® (Tocilizumab)
|
|
16 Jan 2023 |
Cantargia successfully concludes toxicity study with CAN10 antibody ahead of phase I clinical trial application
|
|
16 Jan 2023 |
A novel anti-PD-1 agonist antibody with immunosuppressive effect discovered through joint research between Meiji Seika Pharma and the Foundation for Biomedical Research and Innovation at Kobe
|
|
13 Jan 2023 |
Versanis Announces Initiation of the BELIEVE Global Phase 2b Study of Bimagrumab as a Novel Treatment for Obesity
|
